Gene therapy for rare retinal disorder to cost $425,000 per eye

The price of the gene therapy Luxturna will be $425,000 per eye.

Story highlights

  • Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness
  • Spark Therapeutics set the price for the gene therapy at $425,000 per eye

(CNN)A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.
The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.
    FDA approves gene therapy for a type of blindness